However, there may be other reasons to consider GLP-1 tablets, such as finding injections difficult, travelling often, or experiencing injection site reactions
In November 2023, the FDA granted approval for Zepbound (tirzepatide) for chronic weight management in adults with obesity (body mass index 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbid condition such as hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease
onlinelibrary.wiley.com/doi/full/10.10 Patients who reduced frequency of GLP-1 dosing (from weekly to every other week) are able to maintain weight loss & metabolic syndrome gains, as reported here
It's important to note that GLP-1 agonists can lower blood glucose levels, potentially leading to hypoglycemia, especially in individuals taking other glucose-lowering medications
For L-Buthionine-Sulfoximine (BSO) treatment, wild-type seedlings were transferred to MS10 plates containing 1 mM BSO two days prior to infection
